This is a Phase I/II study designed to evaluate if experimental T cell engaging antibody targeting CD20 AZD5492 is safe, tolerable and efficacious in participants with Relapsed or Refractory B-Cell Malignancies.
≥18 years of age;
Histologically documented CD20+ mature B-cell neoplasm
Large B-cell lymphoma
Follicular lymphoma
Any neoplasm histology not specified in the IC section;
Active CNS involvement in lymphoma;
CNS pathology including but not limited to any history of seizure disorder/epilepsy;
Prior allogeneic HSCT within 180 days, prior autologous HSCT within 90 days, or cell therapy within 90 days of start of therapy;